Tevogen Bio develops immunotherapy solutions for treating cancer, neurological conditions, and viral infections.
Tevogen Bio has raised $3.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Tevogen Bio's investors include KRHP, HMP Partners, HMP Partners, The Patel Family.
Tevogen Bio is headquartered in Warren, United States.
Tevogen Bio develops immunotherapy solutions for treating cancer, neurological conditions, and viral infections.
Tevogen Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tevogen Bio — Funding & Investors." VCBacked, May 12, 2026, https://www.vcbacked.co/company/tevogen-bio. Accessed November 12, 2026.
VCBacked. (2026). Tevogen Bio — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/tevogen-bio
{{cite web |title=Tevogen Bio — Funding & Investors |url=https://www.vcbacked.co/company/tevogen-bio |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Tevogen Bio? Request a listing update